Chacon-Quiros M, Burke R, Gordon A, Herrera-Mora G, Solis-Torres J, Solis-Chaves P, van der Pot W. Retrospective validation of a tissue-preserving breast augmentation approach: from native tissue geometry to surgical practice. Aesthet Surg J. 2026;46(S2):S127-S137. doi: 10.1093/asj/sjag110
Disclosure
Dr. Epstein is a paid investigator in the Motiva U.S. FDA clinical trial and is compensated by Establishment Labs to train surgeons on the Preservé breast augmentation technique. He discloses this relationship in all public communications involving Motiva or Preservé. Dr. Epstein owns stock in Establishment Labs.
What This Study Found
In 111 patients, using 3D imaging and ultrasound before surgery to plan implant position based on each patient's own tissue shape and thickness, rather than a standard formula, the complication rate was 4.5%, with no severe capsular contracture and no implant ruptures, and consistent improvement in breast shape measurements at 12 months.
Key Findings
- 111 patients, primary augmentation or augmentation with a lift, both underarm and fold incisions
- Complication rate: 4.5%
- Zero cases of Grade III/IV capsular contracture, zero implant ruptures
- High patient satisfaction scores
- Consistent, measurable improvement in upper, inner, and outer breast contour and nipple position at 12 months
- Pre-operative 3D imaging (Crisalix) and high-resolution ultrasound used to identify each patient's specific areas of volume deficiency and guide implant selection and placement
Why This Matters for Preservé Patients
This is the study that validates using pre-operative imaging to plan implant selection and placement around each patient's own anatomy, which lines up closely with how Dr. Epstein already talks to patients about individualized planning.
